Curasight A/S (NGM:CURAS)
Sweden · Delayed Price · Currency is SEK · Price in DKK 4.890
-0.490 (-9.11%)
At close: Sep 15, 2025
Curasight Company Description
Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer.
It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers.
The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in Phase II clinical trials to treat non-small cell lung cancer.
Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.
Curasight A/S
| Country | Denmark |
| Founded | 2013 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 4 |
| CEO | Ulrich Krasilnikoff |
Contact Details
Address: Ole Maaløes Vej 3 Copenhagen, 2200 Denmark | |
| Phone | 45 22 83 01 60 |
| Website | curasight.com |
Stock Details
| Ticker Symbol | CURAS |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Ulrich Krasilnikoff | Chief Executive Officer |
| Ulrich Krasilnikoff | Chief Financial Officer |
| Hanne Jensen | Chief Operating Officer |